Biotie acquisition by Acorda
Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc. where Acorda will make a public tender offer in Finland and the…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Global Blood Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock…
Hologic, Inc. $1 Billion Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $1 billion aggregate principal amount of its 5.250% senior notes due 2022…
Cynapsus Therapeutics Inc. $72.5 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common…
Hologic, Inc. $2.5 Billion Senior Secured Credit Facilities Refinancing
Davis Polk advised the administrative agent in connection with the refinancing of Hologic, Inc.’s existing senior secured credit facilities with a $1.5 billion term loan facility and a $1…